About

Science

Learn how we are advancing our pipeline.

Our Approach

Cardiac myosin inhibitors (CMIs) work by targeting myosin – a protein inside heart cells that creates the force for each heartbeat.

In hypertrophic cardiomyopathy (HCM), overactive myosin causes the heart to contract with excessive force. This can lead to thickened heart muscle and declining performance, or how well the heart fills with and pumps blood.

By specifically inhibiting myosin, we aim to improve heart performance.  

About HCM

Moving crowd with blurs of motion.
Two people kayaking on water together.
Two people holding hands walking.

HCM is among the most common rare diseases.

It affects approximately 1 in 500 individuals in the United States. HCM can lead to heart failure, stroke, or sudden cardiac death.

HCM can significantly limit individuals’ ability to exercise, work, or perform routine tasks.

Symptoms can include shortness of breath, chest pain, fatigue, and fainting, which typically worsen with physical activity.

There are two kinds of HCM.

Two-thirds of patients have obstructive HCM (oHCM), where the thickened muscle creates a blockage in the heart's main pumping chamber. Approximately one-third of patients have non-obstructive HCM (nHCM), where there is no obstruction but the muscle is still thickened, making it harder for the heart to work properly.

Pipeline

BHB-1893 is a selective small molecule cardiac myosin inhibitor engineered to improve heart performance in patients with HCM.

Braveheart plans to initiate global late-stage clinical development for BHB-1893 in 2026.

Interested in joining our team?

Reach out to learn more about our openings.

Email Us